Total Payments
$1,770
2024 Payments
$156.69
Companies
28
Transactions
110
Medicare Patients
23,034
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$1,736 (98.1%)
Education$33.87 (1.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,736 | 107 | 98.1% |
| Education | $33.87 | 3 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Relypsa, Inc. | $394.04 | 29 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $261.85 | 17 | $0 (2024) |
| Amgen Inc. | $175.25 | 9 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $160.71 | 9 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $115.07 | 4 | $0 (2022) |
| Mallinckrodt Enterprises LLC | $95.89 | 5 | $0 (2019) |
| Shire North American Group Inc | $74.17 | 5 | $0 (2019) |
| Aurinia Pharma U.S., Inc. | $47.77 | 3 | $0 (2023) |
| Horizon Pharma plc | $44.36 | 3 | $0 (2018) |
| Genentech USA, Inc. | $41.47 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156.69 | 8 | CALLIDITAS THERAPEUTICS US INC. ($28.41) |
| 2023 | $61.26 | 4 | Aurinia Pharma U.S., Inc. ($30.16) |
| 2022 | $150.60 | 8 | Amgen Inc. ($40.24) |
| 2021 | $47.46 | 3 | Otsuka America Pharmaceutical, Inc. ($18.65) |
| 2020 | $166.82 | 8 | Mallinckrodt Hospital Products Inc. ($81.91) |
| 2019 | $402.07 | 27 | Relypsa, Inc. ($126.41) |
| 2018 | $410.96 | 26 | Relypsa, Inc. ($85.25) |
| 2017 | $374.03 | 26 | Relypsa, Inc. ($144.03) |
All Payment Transactions
110 individual payment records from CMS Open Payments — Page 4 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/24/2018 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: Nephrology | ||||||
| 03/13/2018 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: BioOncology/Immunology | ||||||
| 03/12/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Uloric (Drug) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: Gout/Rheumatology | ||||||
| 03/05/2018 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 02/05/2018 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Nephrology | ||||||
| 02/01/2018 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Anemia | ||||||
| 01/31/2018 | Otsuka America Pharmaceutical, Inc. | SAMSCA (Drug) | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: NEPHROLOGY | ||||||
| 01/25/2018 | Shire North American Group Inc | GATTEX (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: INTERNAL MEDICINE | ||||||
| 01/09/2018 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Hyperkalemia | ||||||
| 12/05/2017 | Otsuka America Pharmaceutical, Inc. | SAMSCA (Drug) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: NEPHROLOGY | ||||||
| 12/04/2017 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: Nephrology | ||||||
| 11/29/2017 | Horizon Pharma plc | KRYSTEXXA (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: KRYSTEXXA | ||||||
| 11/01/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: Hyperkalemia | ||||||
| 10/18/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Hyperkalemia | ||||||
| 10/17/2017 | Horizon Pharma plc | KRYSTEXXA (Drug) | Food and Beverage | In-kind items and services | $11.42 | General |
| Category: KRYSTEXXA | ||||||
| 09/22/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Hyperkalemia | ||||||
| 09/18/2017 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: BioOncology/Immunology | ||||||
| 06/28/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $0.84 | General |
| Category: Hyperkalemia | ||||||
| 06/27/2017 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Hyperparathyroidism | ||||||
| 06/27/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $6.67 | General |
| Category: Hyperkalemia | ||||||
| 06/26/2017 | Amgen Inc. | Sensipar (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: Nephrology | ||||||
| 05/22/2017 | Amgen Inc. | Sensipar (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Nephrology | ||||||
| 05/12/2017 | Shire North American Group Inc | NATPARA (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/09/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $12.52 | General |
| Category: Hyperkalemia | ||||||
| 05/09/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $0.55 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 37 | 6,233 | 10,975 | $2.3M | $320,853 |
| 2022 | 39 | 4,753 | 8,093 | $954,009 | $264,157 |
| 2021 | 40 | 5,934 | 13,389 | $956,118 | $265,042 |
| 2020 | 39 | 6,114 | 15,861 | $1.2M | $315,683 |
Total Patients
23,034
Total Services
48,318
Medicare Billing
$1.2M
Procedure Codes
155
All Medicare Procedures & Services
155 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 245 | 668 | $441,722 | $60,082 | 13.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 321 | 510 | $358,051 | $41,765 | 11.7% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 19 | 118 | $231,233 | $31,077 | 13.4% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 322 | 569 | $140,930 | $22,811 | 16.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 106 | 427 | $146,828 | $19,523 | 13.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 138 | 142 | $136,882 | $18,218 | 13.3% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 105 | 416 | $110,323 | $14,694 | 13.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 55 | 105 | $103,490 | $12,801 | 12.4% |
| 82306 | Vitamin d-3 level | Office | 2023 | 283 | 418 | $74,237 | $12,020 | 16.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 93 | 332 | $86,891 | $11,579 | 13.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 101 | 165 | $72,508 | $9,940 | 13.7% |
| 82610 | Cystatin c (enzyme inhibitor) level | Office | 2023 | 231 | 324 | $36,003 | $5,831 | 16.2% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 240 | 400 | $32,712 | $5,295 | 16.2% |
| 80069 | Kidney function blood test panel | Office | 2023 | 337 | 591 | $30,779 | $4,998 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 329 | 596 | $10,728 | $4,969 | 46.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 349 | 648 | $30,210 | $4,906 | 16.2% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 51 | 131 | $28,469 | $3,902 | 13.7% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 227 | 227 | $22,773 | $3,860 | 16.9% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 341 | 631 | $18,849 | $3,551 | 18.8% |
| 83550 | Iron binding capacity | Office | 2023 | 235 | 395 | $20,714 | $3,354 | 16.2% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 342 | 625 | $19,425 | $3,156 | 16.2% |
| 83540 | Iron level | Office | 2023 | 235 | 394 | $15,295 | $2,475 | 16.2% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 126 | 162 | $14,658 | $2,367 | 16.1% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 125 | 180 | $14,461 | $2,362 | 16.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $21,012 | $2,303 | 11.0% |
About Dr. Ralph Stafford, MD
Dr. Ralph Stafford, MD is a Nephrology healthcare provider based in Chattanooga, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1972596013.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ralph Stafford, MD has received a total of $1,770 in payments from pharmaceutical and medical device companies, with $156.69 received in 2024. These payments were reported across 110 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($1,736).
As a Medicare-enrolled provider, Stafford has provided services to 23,034 Medicare beneficiaries, totaling 48,318 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 155 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Nephrology
- Location Chattanooga, TN
- Active Since 08/24/2005
- Last Updated 05/28/2010
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1972596013
Products in Payments
- Veltassa (Drug) $394.04
- ACTHAR (Biological) $210.96
- SAMSCA (Drug) $156.88
- JYNARQUE (Drug) $104.97
- LOKELMA (Drug) $98.37
- Parsabiv (Biological) $77.18
- Sensipar (Drug) $57.83
- FARXIGA (Drug) $50.61
- LUPKYNIS (Drug) $47.77
- KRYSTEXXA (Drug) $44.36
- NATPARA (Drug) $41.77
- Rituxan (Biological) $41.47
- Parsabiv (Drug) $40.24
- Kerendia (Drug) $36.98
- Auryxia (Drug) $28.94
- TARPEYO (Drug) $28.41
- Uloric (Drug) $24.92
- JARDIANCE (Drug) $24.21
- Envarsus XR (Drug) $24.19
- AURYXIA (Drug) $18.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Chattanooga
Rohit Gupta, M.d, M.D
Nephrology — Payments: $10,529
Nephrology $10,529
Hans Yehnert, Md, MD
Nephrology — Payments: $5,326
Nephrology $5,326
Nilesh Patel, M.d, M.D
Nephrology — Payments: $3,184
Nephrology $3,184
John Mccarley, M.d, M.D
Nephrology — Payments: $2,939
Nephrology $2,939
Brant Holt, Md, MD
Nephrology — Payments: $2,929
Nephrology $2,929
Mandeep Grewal, Md, MD
Nephrology — Payments: $2,449
Nephrology $2,449